Home › Research › Health systems and care delivery
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck Leonard M. The Hastings Center report, 2021-06-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Accelerated approval of aducanumab for mild Alzheimer's by the U.S. Food and Drug Administration on June 7, 2021, has generated substantial medical, scientific, and ethical controversy. That approval was contrary to the nearly unanimous judgment of the FDA's Advisory Committee that little reliable evidence existed of significant benefit, even though the drug did reduce β-amyloid. Three major ethical problems were created by this approval: (1) Medicare resources would be unjustly squandered, given the drug's $56,000 annual price and the 3.1 million older potential American patients needing the drug; (2) physicians will feel ethically compelled to provide the drug to desperate, insistent patients, given FDA approval and in spite of side effects of brain bleeds and brain swelling; (3) and false hopes are generated for patients. A needed corrective by the federal government would reduce reimbursement to the bare cost of producing the drug (plus only a modest profit) until a phase IV trial has been successfully completed.
What this study adds
Evidence grade: Low
This article argues that aducanumab's accelerated approval was contrary to the FDA Advisory Committee's judgment that little reliable evidence existed of significant benefit, and it raises concerns about cost, side effects, and false hope. It is a commentary on approval and reimbursement, not new evidence that the drug treats or cures Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fleck Leonard, M. (2021). Alzheimer's and Aducanumab: Unjust Profits and False Hopes. The Hastings Center report. https://doi.org/10.1002/hast.1264
Vancouver
Fleck Leonard M. Alzheimer's and Aducanumab: Unjust Profits and False Hopes. The Hastings Center report. 2021. doi:10.1002/hast.1264. PMID: 34156732.
BibTeX
@article{fleckleonard2021-34156732,
author = {Fleck Leonard, M.},
title = {{Alzheimer's and Aducanumab: Unjust Profits and False Hopes}},
journal = {The Hastings Center report},
year = {2021},
doi = {10.1002/hast.1264},
pmid = {34156732},
url = {https://doi.org/10.1002/hast.1264}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- That approval was contrary to the nearly unanimous judgment of the FDA's Advisory Committee that little reliable evidence existed of significant benefit, even though the drug did reduce β-amyloid.
Why it matters
This article argues that aducanumab's accelerated approval was contrary to the FDA Advisory Committee's judgment that little reliable evidence existed of significant benefit, and it raises concerns about cost, side effects, and false hope. It is a commentary on approval and reimbursement, not new evidence that the drug treats or cures Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 16/100
Report — not peer-reviewed. It scored 25 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 24 of the 97 points we could judge it on, which is 25 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (The Hastings Center report) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 3 / 10 | Report — not peer-reviewed. Named source is an organizational report, not a journal article. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 51 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 5.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Leonard Michael Fleck: h-index 20 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34156732) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 97 points we could judge it on is 25 out of 100. |
| Total | 25 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.